Dr. Sgourakis’ research focuses on understanding the intricate molecular mechanisms that determine the vast repertoire of peptide antigens displayed by the proteins of the Major Histocompatibility Complex for immune surveillance by T cells and Natural Killer cells.
It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children's Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.
Training the next generation of investigators has long been a priority at Children's Hospital of Philadelphia. There are numerous opportunities throughout the year to celebrate the accomplishments of our trainees and honor their commitment to science.
Welcome back to our weekly roundup of pediatric research news from The Children's Hospital of Philadelphia. This week, as many students head back to school, the American Academy of Pediatrics (AAP) is strengthening its advocacy to protect individual and public health by calling for an end to nonmedical exemptions from school vaccine requirements.
It started at the end of a long day. Jessica Panzer, MD, PhD, then just a few weeks into her pediatric neurology residency at The Children’s Hospital of Philadelphia, was about to go home. Instead, she was called to the emergency room to consult on a 3-year-old girl who could barely walk.